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Objective. To determine the effect of selexipag,
an oral, selective IP prostacyclin receptor agonist, on
the frequency of attacks of Raynaud’s phenomenon
(RP) in patients with systemic sclerosis (SSc).
Methods. Patients with SSc-related RP were ran-
domized 1:1 to placebo (n = 38) or selexipag (n = 36) in
individualized doses (maximum of 1,600 lg twice daily)
during a 3-week titration period. The primary end point
was the weekly average number of RP attacks during the
study maintenance period, analyzed using a Bayesian
approach with a negative binomial model adjusted for
baseline number of RP attacks. Other outcome measures
included Raynaud’s Condition Score (RCS), RP attack
duration, and treatment-emergent adverse events (AEs).
Results. Baseline characteristics were comparable
between treatment groups. For 83.3% of patients, the
individualized maintenance dosage of selexipag was ≤800
lg twice daily. No significant difference was observed
between placebo and selexipag in weekly average number
of electronic diary (eDiary)–recorded RP attacks during
the maintenance period (14.2 attacks during the mainte-
nance period and 21.5 attacks during the baseline week
in the placebo group [n = 32] versus 18.0 attacks during
the maintenance period and 22.4 attacks during the
baseline week in the selexipag group [n = 27]; adjusted
mean treatment difference of 3.4 in favor of placebo).
No significant treatment effect was observed on RCS or
RP attack duration. In the double-blind period, 86.8% of
placebo-treated patients and 100% of selexipag-treated
patients reported ≥1 AE; 55.3% and 91.7%, respectively,
reported ≥1 prostacyclin-associated AE.
Conclusion. Treatment with selexipag did not
reduce the number of RP attacks compared with pla-
cebo. The safety profile of selexipag was similar to that
previously reported. This study provides important
information about the feasibility of eDiary reporting of
RP attacks in clinical trials.
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Raynaud’s phenomenon (RP) is experienced by
>90% of patients with systemic sclerosis (SSc), often as
the first symptom of the disease (1–3). RP is part of
the spectrum of vasculopathy associated with SSc,
which also includes digital ulceration and critical digital
ischemia (2). It is an important clinical manifestation
of the disease, as it is thought that vasculopathy may
play a key role in the early pathogenesis of SSc (4). RP
occurs due to episodic, reversible vasospasm of the
small arteries and arterioles, usually in the fingers and
toes, and is mainly triggered by cold or emotional stress
(5,6). In addition, RP secondary to SSc is linked with
structural changes of the vasculature, resulting in blood
vessel narrowing and impairment of blood flow (5).
Because RP is burdensome, improvements in RP have
been linked to better quality of life (7,8).
Management of RP is challenging and requires a
multifaceted approach, including risk factor avoidance
and targeted drug therapy (2), such as calcium-channel
blockers (9) and, more recently, at least in patients with
severe SSc-related RP, phosphodiesterase V inhibitors
(10–12). Angiotensin receptor blockers are sometimes
recommended, but there is little evidence to support
their efficacy (13). Intravenous prostanoids, particularly
iloprost infusions, are recommended for patients with
severe RP when treatment with other agents has failed
(2,9). Although intravenous iloprost has demonstrated
efficacy in decreasing severity, frequency, and duration
of RP attacks in patients with SSc (14–18), intravenous
administration is burdensome. Currently, there is limited
evidence for the benefit of oral prostacyclin analogs in
patients with RP (8). Therefore, there is a need to iden-
tify oral therapies that act on the prostacyclin receptor
for the management of RP secondary to SSc.
Selexipag is an oral, selective IP prostacyclin
receptor agonist that has recently been approved for
the long-term treatment of pulmonary arterial hyper-
tension (PAH) in adults with World Health Organiza-
tion functional class II/III symptoms (19,20). The
present study aimed to determine the effect of selexi-
pag on the frequency of RP attacks in patients with RP
secondary to SSc.
PATIENTS AND METHODS
Study design. This was a multicenter, double-blind,
randomized, placebo-controlled, parallel-group, phase II
study comprising a 2–4-week single-blind placebo run-in per-
iod, an 8-week treatment period (3-week titration, 5-week
maintenance), and a 30-day posttreatment safety follow-up
period. The baseline week was the last 7 days before random-
ization during the run-in period. Patients were randomized in
a 1:1 ratio to placebo or selexipag, stratified by the presence
or absence of digital ulcers at baseline. Data on RP attacks
were collected using an electronic diary (eDiary).
During the single-blind run-in period, patients
received placebo twice daily. This run-in period was designed
primarily to determine eligibility with respect to RP attack
frequency. In the 3-week titration period, selexipag or match-
ing placebo was initiated at a dosage of 200 lg twice daily
and was increased every 3 days in increments of 200 lg until
unmanageable adverse effects associated with prostacyclin use
(e.g., headache or diarrhea) developed. The dose was then
either continued or decreased by 200 lg in both daily
dosages, and this was considered to be the individualized
highest tolerated dosage. The maximum dosage allowed was
1,600 lg twice daily. During the maintenance period, dose
increases were not permitted; however, dose reductions for
tolerability reasons and subsequent titration to the dose previ-
ously reached were allowed. The individualized maintenance
dose was defined as the dose that the patient was exposed to
for the longest duration during the maintenance period.
The study was conducted during the winter months in
the Northern Hemisphere to minimize seasonal variability. At
screening, patients were trained by the investigator in how to
recognize an attack as well as the information to be recorded
in the eDiary (number of RP attacks per day; attack duration
in minutes). An RP attack was defined as an episode of at
least a 2-phase color change in the fingers in response to cold
exposure or emotion, consisting of pallor and/or cyanosis and
reactive hyperemia associated with finger discomfort. Written
informed consent was provided by all patients. Ethical
approval was received from the independent ethics committee
or institutional review board of all participating centers prior
to study commencement. The study was conducted in accor-
dance with the principles of the Declaration of Helsinki. A list
of the Raynaud Study Investigators is provided in Appendix A.
Patient selection. Eligible patients were age ≥18 years
with a diagnosis of SSc according to the American College of
Rheumatology (ACR)/European League Against Rheumatism
(EULAR) 2013 classification criteria (total score of ≥9,
including a score of 3 for the RP item) (21). Patients were
required to have had ≥7 RP attacks on ≥5 different days dur-
ing the baseline week and ≥80% eDiary compliance during
the run-in period. We excluded patients with a history of
other conditions that can affect RP evaluation (for example,
surgery [cervicothoracic sympathectomy, recent amputation,
debridement] or recent treatment with botulinum toxin).
Patients who received prostacyclin or prostacyclin analogs
within 3 months of the screening visit were not eligible.
Patients were permitted to take calcium-channel blockers,
nitrates or nitric oxide donors, endothelin receptor antago-
nists, alpha-blockers, antithrombotic agents, nonsteroidal
antiinflammatory agents, angiotensin-converting enzyme inhi-
bitors, beta-blockers, clonidine, systemic corticosteroids, and
fluoxetine during the study, provided that the dose had been
stable in the month prior to screening and remained stable
during the treatment period. Complete inclusion/exclusion cri-
teria are provided in Supplementary Table 1, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.40242/abstract.
Study outcome measures. The primary efficacy end
point was the weekly average number of RP attacks during the
maintenance period. Other prespecified efficacy end points
included number and proportion of patients with weekly
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average number of RP attacks in categories of improved
(change from baseline week of at least –15%), stable (change
from baseline week of between –15% and 15%), and worsened
(change from baseline week of >15%) during the maintenance
period; change from baseline week to week 8 in the weekly
average RP attack duration following randomization; change
from baseline week to each postbaseline week in the weekly
average Raynaud’s Condition Score (RCS) (22) following ran-
domization; number of new digital ulcers and number of base-
line digital ulcers completely healed at week 8, and changes
from baseline to week 8 in quality of life, as measured by the
overall Scleroderma Health Assessment Questionnaire (23),
the Health Assessment Questionnaire disability index (HAQ
DI) (24), and the hand components of the HAQ DI. Safety
end points included treatment-emergent adverse events (AEs)
and laboratory assessments.
Statistical analysis. Efficacy end points were analyzed
on the per-protocol set, which included all patients who had
≥7 RP attacks on ≥5 days during the baseline week, did not
receive forbidden concomitant medication from the start of
the run-in period until end of treatment, did not prematurely
discontinue treatment before day 30, and completed ≥70% of
the eDiary RP assessments during the maintenance period.
The primary efficacy end point was analyzed using a negative
binomial model adjusted for the baseline number of RP
attacks to assess the following joint proof-of-concept criteria
in a Bayesian framework: statistical significance was achieved
if there was a high probability (≥0.95) that the difference in
the mean weekly average number of RP attacks (selexipag
minus placebo) was <0 during the maintenance period (i.e.,
the probability of a difference of <0 was ≥0.95); clinical signif-
icance was achieved if the probability of a difference of <–4
was ≥0.5. Missing data were minimized by using the per-
protocol set for the primary analysis. Weekly rates of RP
attacks were standardized based on each patient’s follow-up
time in the maintenance period, to account for different
follow-up times and/or missing days of RP attacks.
Power and sample size were determined using simula-
tions based on the assumed total number of RP attacks at
baseline and during the maintenance period. With 25 patients
per arm qualifying for the per-protocol set, the operating
characteristics of the Bayesian approach were a true-positive
probability of >85% to fulfill both proof-of-concept criteria if
the true difference between the means of the weekly average
number of RP attacks during the maintenance period was at
least 5.25, and a false-positive probability of <1% to fulfill
Figure 1. Patient disposition. * = Six patients were excluded from the placebo per-protocol set (PPS), due to premature study treatment discontin-
uation (before day 30) (n = 2), ≥30% missing data for assessment of Raynaud’s phenomenon (RP) during the maintenance period (n = 2), and the
concomitant use of forbidden medication (n = 2). † = Nine patients were excluded from the selexipag per-protocol set, due to premature study
treatment discontinuation (before day 30) (n = 7), ≥30% missing data for RP assessment during the maintenance period (n = 1), and <7 RP
attacks/RP attacks not experienced on ≥5 different days prior to randomization (n = 1). FAS = full analysis set (all randomized patients); SAE =
serious adverse event.
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both proof-of-concept criteria if the true difference between
the means was 0, assuming at least a 30% reduction from the
baseline week with ≥17.5 RP attacks. Based on this, it was
determined to randomize 35 patients per treatment arm. A
prespecified subgroup analysis of the primary efficacy variable
was conducted based on the presence/absence of digital ulcers
at baseline, number of RP attacks during the baseline week
(≤17, >17), smoking status at screening (smoker, nonsmoker/
former smoker), and use/no use of calcium-channel blockers
at baseline.
Descriptive statistics, counts and percentages (categor-
ical variables), and means and SDs (continuous variables)








Male 7 (18.4) 7 (19.4) 14 (18.9)
Female 31 (81.6) 29 (80.6) 60 (81.1)
Age, mean  SD years 52.6  11.9 52.7  12.2 52.6  12.0
Race, no. (%)
White 34 (89.5) 35 (97.2) 69 (93.2)
Asian 3 (7.9) – 3 (4.1)
Other 1 (2.6) 1 (2.8) 2 (2.7)
SSc subset, no. (%)
Limited cutaneous 22 (57.9) 22 (61.1) 44 (59.5)
Diffuse cutaneous 14 (36.8) 12 (33.3) 26 (35.1)
Other 2 (5.3) 2 (5.6) 4 (5.4)
Time since SSc diagnosis, mean  SD years† 7.4  6.3 7.3  7.2 7.3  6.7
Time since first non-RP symptom, mean  SD years† 8.5  6.4 9.5  6.8 9.0  6.6
Time since first RP symptom, mean  SD years† 13.4  10.7 14.9  10.7 14.1  10.7
PAH and/or ILD, no. (%)‡§
PAH 0 (0.0) 0 (0.0) 0 (0.0)
ILD 10 (26.3) 4 (11.1) 14 (18.9)
Unknown/not answered 3 (7.9) 3 (8.3) 6 (8.1)
SSc-related antibodies, no. (%)‡
Anticentromere 19 (50.0) 16 (44.4) 35 (47.3)
Anti–topoisomerase I 12 (31.6) 6 (16.7) 18 (24.3)
Anti–RNA polymerase III 5 (13.2) 4 (11.1) 9 (12.2)
Unknown 1 (2.6) 2 (5.6) 3 (4.1)
RP attacks in the baseline week, mean  SD 21.6  14.7 22.1  16.1 21.8  15.3
History of digital ulcers, no. (%) 27 (71.1) 16 (44.4) 43 (58.1)
Digital ulcers present at baseline, no. (%) 7 (18.4) 4 (11.1) 11 (14.9)
Smoking status, no. (%)
Current smoker 6 (15.8) 6 (16.7) 12 (16.2)
Former smoker 9 (23.7) 11 (30.6) 20 (27.0)
Nonsmoker 23 (60.5) 19 (52.8) 42 (56.8)
Baseline use of CCBs, no. (%) 24 (63.2) 15 (41.7) 39 (52.7)
* SSc = systemic sclerosis; RP = Raynaud’s phenomenon; CCBs = calcium-channel blockers.
† Calculated from date of randomization.
‡ Classes not mutually exclusive.
§ Data on pulmonary arterial hypertension (PAH)/interstitial lung disease (ILD) collected as part of the American
College of Rheumatology/European League Against Rheumatism criteria (21).






Average number of RP attacks during baseline week, mean  SD 21.5  13.5 22.4  15.9
Weekly average number of RP attacks during maintenance period, mean  SD 14.2  10.3 18.0  14.1
Statistical inference
Posterior weekly average number of RP attacks during the maintenance phase,
mean  SD†
12.5  1.1 15.9  1.5
Adjusted treatment difference, mean (90% CI)†‡ 3.4 (0.4–6.6)
P for difference <0† 0.03
P for difference <–4† 0.00
* Per-protocol set. 90% CI = 90% confidence interval.
† Statistics from negative binomial model in Bayesian framework.
‡ Selexipag minus placebo, adjusted for the average number of attacks of Raynaud’s phenomenon (RP) during the baseline week.
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were provided without imputation for missing data. Between-
group changes from baseline to week 8 in the RCS were com-
pared using a nonparametric analysis of covariance adjusted
for the baseline score. Safety analyses were performed on the
safety analysis set, which included all patients who received
≥1 dose of study treatment.
RESULTS
Patient disposition and baseline characteristics.
Ninety-two patients were screened between November
2014 and February 2015 from 16 centers in France,
Germany, and the UK. Seventy-four patients were ran-
domized to placebo (n = 38) or selexipag (n = 36), of
whom 59 (placebo n = 32; selexipag n = 27) formed the
per-protocol set (Figure 1).
Baseline demographics and clinical characteris-
tics were similar between all randomized patients
(Table 1) and the per-protocol set (see Supplementary
Table 2, http://onlinelibrary.wiley.com/doi/10.1002/art.
40242/abstract). The treatment arms were generally
similar, although more patients in the placebo group
had a history of digital ulcers (71.1%) compared with
the selexipag group (44.4%). Baseline use of calcium-
channel blockers in the per-protocol set was greater in
placebo-treated patients (71.9%) compared with selexi-
pag-treated patients (33.3%) (see Supplementary Table 2).
Dosing and exposure. Of all randomized patients,
71.1% (27 of 38) in the placebo group had an individu-
alized maintenance dose corresponding to 1,600 lg
twice daily, while 83.3% (30 of 36) of patients receiving
selexipag had an individualized maintenance dose of
≤800 lg twice daily (median 600 [interquartile range
200–800]) (see Supplementary Table 3, http://onlinelibrary.
wiley.com/doi/10.1002/art.40242/abstract). The median
duration of exposure to study drug for all randomized
patients in the double-blind period was 55.5 days
(interquartile range 54.0–57.0 days) in the placebo
group and 55.5 days (interquartile range 50.5–56.0
days) in the selexipag group.
Primary efficacy end point. During the mainte-
nance period, there was a decrease from the baseline
week in the weekly average number of RP attacks for
both the placebo and selexipag groups (Table 2). As
the probabilities of observing a difference (selexipag
minus placebo) of <0 (statistical significance) and of
<–4 (clinical efficacy) in the mean weekly average num-
ber of RP attacks were below the proof-of-concept crite-
ria of ≥0.95 and ≥0.5, respectively (observed probabilities
0.03 and 0.00, respectively), the primary objective was
not met (Table 2 and Figure 2). Similar results were
observed in the prespecified subgroups (Figure 3).
Other end points. The weekly average number
of RP attacks during the maintenance period improved
in 81.3% of placebo-treated patients and in 63.0% of
selexipag-treated patients; it remained stable in 12.5%
and 22.2% of patients, respectively, and worsened in
6.3% and 14.8% of patients, respectively. During the
baseline week, the average RP attack duration was 21.5
minutes in the placebo group and 24.2 minutes in the




Figure 2. Posterior distribution of weekly Raynaud’s phenomenon
(RP) attack rate in selexipag-treated patients (A) and placebo-treated
patients (B), and difference in weekly RP attack rate between treat-
ment arms (per-protocol set) (C). The probabilities of observing a dif-
ference (selexipag minus placebo) of <0 (statistical significance; right
vertical bar) and of <–4 (clinical efficacy; left vertical bar) in the
mean weekly average number of RP attacks were below the proof-of-
concept criteria of ≥0.95 and ≥0.5, respectively (observed probabilities
0.03 and 0.00, respectively).
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average RP attack duration at week 8 was 4.6  26.5
minutes in the placebo group and 2.7  17.0 minutes
in the selexipag group (n = 19 for both groups). The
mean RCS at baseline was 3.3 in placebo-treated
patients (n = 30) and 4.0 in selexipag-treated patients
(n = 25). No difference was observed between placebo
and selexipag in changes from baseline in RCS at any
time during the study (data not shown).
At baseline, 5 placebo-treated patients (15.6%)
had a total of 8 digital ulcers, and 3 selexipag-treated
patients (11.1%) had a total of 3 digital ulcers (see
Supplementary Table 2, http://onlinelibrary.wiley.com/
doi/10.1002/art.40242/abstract). The number of new digi-
tal ulcers reported during the double-blind period was
low in both groups (0.2 per patient in the placebo group
and 0.4 per patient in the selexipag group). At the end
of treatment, 5 of the 8 baseline digital ulcers were
healed in the placebo group and all baseline digital
ulcers were healed in the selexipag group. There were
no differences between treatment groups in the quality-
of-life assessments (data not shown).
Safety and tolerability. Overall, 86.8% of pla-
cebo-treated patients and 100% of selexipag-treated
Figure 3. Forest plot of summary statistics of weekly attacks of Raynaud’s phenomenon (RP) from posterior distribution of negative binomial
Bayesian model (subgroup analyses; per-protocol set). np = number of patients receiving placebo; na = number of patients receiving active treat-
ment; P† = probability that the difference between the treatment means (selexipag minus placebo) for weekly average number of RP attacks in
the maintenance period is <0; 90% CI = 90% confidence interval; DU = digital ulcer; CCBs = calcium-channel blockers.





Patients with AEs 33 (86.8) 36 (100.0)
Patients with SAEs 4 (10.5) 2 (5.6)
Patients with AEs leading to study
drug discontinuation
2 (5.3) 6 (16.7)†
AEs occurring in ≥10% of patients in
either treatment group
Headache 14 (36.8) 23 (63.9)
Nausea 4 (10.5) 13 (36.1)
Diarrhea 5 (13.2) 10 (27.8)
Dizziness 2 (5.3) 8 (22.2)
Pain in extremity 2 (5.3) 8 (22.2)
Pain in jaw 0 (0.0) 8 (22.2)
Fatigue 3 (7.9) 6 (16.7)
Myalgia 2 (5.3) 5 (13.9)
Arthralgia 1 (2.6) 5 (13.9)
Nasopharyngitis 6 (15.8) 4 (11.1)
Flushing 1 (2.6) 4 (11.1)
Back pain 0 (0.0) 4 (11.1)
Raynaud’s phenomenon worsening 4 (10.5) 2 (5.6)
Abdominal pain, upper 4 (10.5) 1 (2.8)
Skin ulcer 5 (13.2) 0 (0.0)
* Safety analysis set for the double-blind treatment period. Values are
the number (%). SAEs = serious adverse events.
† Includes 1 patient who discontinued due to an AE (headache) with
onset during the run-in period.
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patients reported ≥1 AE (Table 3). Most AEs were
reported as mild or moderate in intensity (34.2% and
44.7%, respectively, with placebo; 16.7% and 61.1%,
respectively, with selexipag). Serious AEs (SAEs)
reported in the placebo group were RP worsening
(2 patients), bronchitis (1 patient), and skin ulcer
(1 patient); SAEs reported in the selexipag group were
musculoskeletal chest pain (1 patient) and pulmonary
hypertension (1 patient). In the placebo group, AEs
leading to study drug discontinuation were bronchitis
and RP worsening. In the selexipag group, all but 1 AE
(syncope) leading to study drug discontinuation were
AEs typically associated with therapies targeting the
prostacyclin pathway. At least 1 AE typically associ-
ated with therapies targeting the prostacyclin pathway
occurred in 55.3% of placebo-treated patients and
91.7% of selexipag-treated patients, of which headache
was the most frequently reported (36.8% in the placebo
group, 63.9% in the selexipag group). Most of these
AEs were reported as mild or moderate in intensity
(61.9% and 33.3%, respectively, with placebo; 36.4%
and 48.5%, respectively, with selexipag). There were no
deaths during the study.
DISCUSSION
The primary objective of the study was to evalu-
ate the effect of selexipag on the frequency of RP
attacks in patients with RP secondary to SSc. The ra-
tionale for this evaluation included the observation that
other drugs targeting the prostacyclin pathway (e.g.,
intravenous iloprost) have shown some efficacy in RP
secondary to SSc (18). However, selexipag did not
reduce the number of RP attacks compared with pla-
cebo, and therefore the study did not meet its primary
objective. The safety profile of selexipag was consistent
with that observed previously in studies of patients with
PAH (19,25), with no new safety events identified.
Recent systematic reviews have noted that there
have been few randomized controlled trials in RP,
including in SSc-related RP (26–29). This dearth of
studies is related to the complexities of study design in
RP, which includes the need to run trials during the
winter months to minimize the effects of seasonality
(30). Despite its negative findings, our study is impor-
tant because it draws attention to a number of learning
points that will help to optimize clinical trial design.
One particular point of note for future trial design is
the issue of a placebo response in studies of RP. The
placebo effect is often a confounder in the evaluation of
RP in a clinical trial setting (12,31). In our study, the
placebo effect was notable, with many placebo-treated
patients reporting good outcomes. Patient-reported
outcomes may be particularly sensitive to the placebo
effect (30); it may be that placebo-treated patients
experience fewer AEs and subsequently report better
outcomes compared with patients receiving active treat-
ment who are subject to side effects. Another potential
contributing factor may be the difference between
groups in the number of tablets taken; a greater pro-
portion of placebo-treated patients reached a higher
placebo-equivalent dose and therefore received more
tablets. Taking more tablets may be associated with
an increased placebo effect (32). Also, by specifically
recruiting patients who report a high number of RP
attacks, we may have selected a population in which
the placebo effect is particularly apparent.
The timing and time period of the study may have
imposed certain limitations. As stated earlier, seasonal
variability is a potential confounding factor in studies
that evaluate RP (30). In this study, the observation per-
iod was limited to the winter season to avoid seasonal
variability. This restriction affected the time allowed to
titrate selexipag up to the individualized highest toler-
ated dose, and further increases were not permitted
during the maintenance period. In the Prostacyclin
Receptor Agonist In Pulmonary Arterial Hypertension
study, the titration period for selexipag (up to 1,600 lg
twice daily) was 12 weeks (19), while in our study, for the
same maximum allowed dose, selexipag was titrated to
an individualized highest tolerated dose over 3 weeks.
The short titration period in the present study meant
that patients had a limited amount of time to adjust to
AEs associated with selexipag treatment and, as a result,
may not have reached their efficacious dose.
Structural vasculopathy and vasospasm are fea-
tures of SSc (33), and it is possible that treatment act-
ing to restore vasoreactivity could lead to greater
awareness of RP attacks, thereby masking a potential
treatment effect. This potential confounding factor is
likely to be more acute over a short observation period,
and a longer observation period may be warranted to
discern any potential treatment effect.
The number of new digital ulcers reported dur-
ing the double-blind period was low in both treatment
groups and lower than that in previous studies with
double-blind or open-label treatment that specifically
focused on digital ulcers (34–38). However, this study
was not designed or powered to assess the impact of
selexipag on digital ulcers.
Although not fully understood, the pathogenesis
of RP secondary to SSc is linked to structural and
functional changes in the vasculature leading to
impaired blood flow and an imbalance in the levels of
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neurotransmitters controlling vasodilation and vasocon-
striction, and SSc-related RP has been associated with
smoking, hormonal changes, and genetic factors (39).
As there is evidence that selexipag is efficacious in
other forms of vasculopathy and some evidence that
other therapies targeting the prostacyclin pathway can
have a positive effect on RP, differences in efficacy due
to the route of administration also need to be consid-
ered. Intravenous iloprost has shown efficacy in reduc-
ing the number, severity, and duration of RP attacks
(14–17,40,41); however, consistent benefits have not
been seen in trials evaluating oral iloprost (42–44). This
raises the question of whether the route of administra-
tion of selexipag may have an impact on the potential
for a treatment response. One might consider targeting
SSc vasculopathy with IP prostacyclin receptor agonists,
such as selexipag, but via a different mode of adminis-
tration. Furthermore, future studies may include the
use of objective measurements to assess clinically rele-
vant end points in SSc vasculopathy.
There are a number of additional points to note
about the design and conduct of our study. First,
patients used an eDiary to record the frequency and
duration of their RP attacks. Compared with a paper
diary, this electronic tool was expected to facilitate bet-
ter compliance and accuracy (45). Indeed, 95.9% of
patients were compliant in completing the eDiary; only
2 of 38 placebo-treated patients and 1 of 36 selexipag-
treated patients were excluded from the per-protocol
set due to lack of eDiary compliance, a key finding that
benchmarks this novel method of recording RP attacks
for future studies. Second, despite the short enrollment
period, it was feasible to recruit a good number of
patients who were representative of the patients with
SSc seen in daily clinical practice; the enrolled popula-
tion was comparable to that reported in large cohorts
such as the EULAR Scleroderma Trials and Research
group database (1). Third, a precise definition of RP
attacks, based on the ACR/EULAR criteria (21), was
used in this study, while earlier studies of intravenous
or oral treatments for RP used less precise and incon-
sistent definitions of RP attacks.
In conclusion, treatment with selexipag in the
present study did not reduce the number of RP attacks
compared with placebo in patients with RP secondary
to SSc. The safety profile of selexipag was consistent
with that previously observed in studies of patients with
PAH, with no new safety events identified. Some
aspects of this study may offer a potentially robust tem-
plate for future studies in RP secondary to SSc, includ-
ing the use of the eDiary as an innovative tool in
disease monitoring.
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APPENDIX A: THE RAYNAUD STUDY INVESTIGATORS
The Raynaud Study Investigators are as follows: C. Agard
(CHU de Nantes–Ho^pital Ho^tel Dieu, PHUS–Service de Medecine
Interne, Nantes, France), A. Ambach (Otto-von-Guericke-Universit€at
Magdeburg, Universit€atsklinik f€ur Dermatologie und Venerologie, Mag-
deburg, Germany), M. Anderson (University Hospital Aintree–Rheuma-
tology Department, Liverpool, UK), M. Buch (Leeds Institute of
Rheumatic and Musculoskeletal Medicine, Leeds, UK), P. Carpentier
(CHU Grenoble–Ho^pital Michallon, Service de medecine vasculaire,
Grenoble, France), C. P. Denton (The Royal Free Hospital, Department
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of Rheumatology, Royal Free London NHS Foundation Trust, London,
UK), J. Distler (Friedrich-Alexander-Universit€at Erlangen-N€urnberg,
Medizinische Klinik 3, Rheumatologie und Immunologie, Erlangen,
Germany), E. Feist (Universit€atsmedizin Berlin, Medizinische Klinik mit
Schwerpunkt, Rheumatologie und Klinische Immunologie, Berlin, Ger-
many), E. Hachulla (CHRU de Lille–Ho^pital Claude Huriez, Service de
Medecine Interne, Lille, France), A. Herrick (Salford Royal NHS Foun-
dation Trust, Rheumatic Diseases Centre, Clinical Research Facility,
Salford, UK), R. K€onig (Kerckhoff-Klinik GmbH, Abteilung für Rheu-
matologie und Klinische Immunologie, Bad Nauheim, Germany),
P. Moinzadeh (Uniklinik K€oln, Klinik und Poliklinik f€ur Dermatologie
und Venerologie, K€oln, Germany), L. Mouthon (Ho^pital Cochin, Ser-
vice de Medecine Interne, Paris, France), J. Pauling (Royal National
Hospital for Rheumatic Diseases, Department of Rheumatology, Bath,
UK), G. Riemekasten (Universit€atsmedizin Berlin, Medizinische Klinik
mit Schwerpunkt, Rheumatologie und Klinische Immunologie, Berlin,
Germany), A. Schwarting (Universit€atsmedizin der Johannes Gutenberg-
Universit€at Mainz, I. Medizinische Klinik und Poliklinik, Rheumatologie
und klinische Immunologie, Mainz, Germany), J. Sibilia (Ho^pital de
Hautepierre, Service de Rhumatologie, Strasbourg, France).
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